T细胞性淋巴瘤组织CD56的检测及其与EB病毒的关系

目的探讨Ｔ细胞性淋巴瘤（ＴＣＬ）中ＣＤ５６的表达情况及ＣＤ５６阳性表达同爱波斯坦－巴尔病毒（ＥｐｓｔｅｉｎＢａｒＶｉｒｕｓ,ＥＢＶ）感染的关系。方法对４６例ＴＣＬ进行ＣＤ５６的免疫组织化学ＬＳＡＢ法检测及ＥＢＥＲｓ的原位杂交检测。结果（１）４６例ＴＣＬ中８例ＣＤ５６阳性（１７．４％）,其中鼻腔、咽部和口腔阳性率最高（５／１７例,２９．４％）。弥漫性大细胞型淋巴瘤ＣＤ５６阳性率最高（６／１６例,３７．５％）。（２）４６例ＴＣＬ中２４例ＥＢＥＲｓ阳性（５２．２％）。（３）８例ＣＤ５６阳性病例中,４例ＥＢＥＲｓ阳性。结论ＣＤ５６的表达同ＴＣＬ发生部位和类型有一定关系。ＣＤ５６阳性表达与ＥＢ病毒感染未发现相关性     

EB病毒潜伏感染在不同部位T细胞淋巴瘤中的表达

目的：探讨不同部位Ｔ细胞淋巴瘤（ＴＭＬ）与ＥＢ病毒（ＥＢＶ）感染的关系。方法：对１００例不同部位的ＴＭＬ（结内４０例、结外６０例），采用原位杂交法检测肿瘤细胞ＥＢＶ编码的ＲＮＡ（ＥＢＥＲ１／２）。结果：（１）１００例中ＥＢＥＲ１／２检出率４８％（４８／１００），结内ＴＭＬ检出率３０％（１２／４０），结外ＴＭＬ检出率６０％（３６／６０），结内、结外ＥＢＶ检出率差异有非常显著意义（Ｐ＜０．０１）。（２）结外呼吸道ＴＭＬＥＢＥＲ１／２检出率鼻腔、鼻咽、口咽和肺分别是８８．９％（１６／１８）、７１．４％（５／７）、４７．６％（１０／２１）、３３．３％（１／３）。（３）胃肠道、软组织ＴＭＬＥＢＥＲ１／２检出率分别是１６．７％（１／６）、３３．３％（１／３）。结论：ＥＢＶ感染在不同部位ＴＭＬ中的表达具有明显部位限制性，特别是鼻腔、鼻咽的ＴＭＬ与ＥＢＶ关系最密切，其ＥＢＥＲ１／２检出率明显高于身体其它部位Ｔ细胞淋巴瘤     

间变性淋巴瘤激酶阴性的间变性大细胞淋巴瘤中C-MYC和PD-L1基因及蛋白表达的研究

目的:探讨C-MYC和PD-L1基因和蛋白在间变性淋巴瘤激酶阴性的间变性大细胞淋巴瘤（ALK －ALCL）患者中的表达,探讨两者在ALK －ALCL发病机制中的作用以及与临床病理特征的关系。 方法:收集福建省立医院病理科2003年1月至2017年1月ALK －ALCL患者3...     

系统性间变性大细胞淋巴瘤的免疫组织化学特征

目的:探讨系统性间变性大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)的免疫组织化学特征.方法:回顾性分析48例系统性ALCL的免疫组织化学和10例系统性ALCL原位杂交技术检测EBER(EBV-encoded small RNA)的结果.结果:48例系统性ALCL的肿瘤细胞均表达CD30,而间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)在41.7％(20/48)的病例阳性,其他指标阳性率为CD2为65.0％(26/40),CD3为36.2％(17/47),CD4为72.7％(16/22),CD5为42.9％(15/35),CD7为16.7％(5/30),上皮细胞膜抗原(epithelial membrane antigen,EMA)为65.6％(21/32),T细胞胞质内抗原(T-cell intracellular antigen-1,TIA-1)为79.2％(19/24),颗粒酶B(granzyme B-producing Breg,GrB)为70.0％(14/20).所有病例的B细胞标志(CD20,PAX5,CD79a)均阴性.10例系统性ALCL有2例出现部分肿瘤性大细胞EBER阳性.结论:CD30和ALK是诊断ALCL关键及较为特异的免疫指标;有时出现人类疱疹病毒第四型(Epstein-Barr virus,EBV)感染并不能排除ALCL的诊断.     

间变性大细胞淋巴瘤的阵列比较基因组杂交分析

目的 利用阵列比较基因组杂交(aCGH)技术探讨间变性大细胞淋巴瘤(ALCL)的分子遗传学异常.方法 采用免疫组织化学EnVision法及荧光原位杂交技术对25例ALCL进行间变性淋巴瘤激酶(ALK)蛋白及基因分子遗传学异常的检测;利用aCGH技术进行全基因组遗传学检测,并对检测结果与ALCL的ALK蛋白表达进行相关性分析.结果 25例ALCL中均有染色体片段的扩增/缺失,且扩增多于缺失.其中＞50％病例中存在染色体区域5p13.2、3q1.1、2q21.3、3p25.1、14q32.33、17q21.2的获得;30％ ～ 50％病例中存在染色体区域4q27、6p22.1、20p11.21、2q22.3、4q35.1、1p36.22、8p23.1、8p12、11q14.1、12q13.13、19p13.3的获得;36.0％ (9/25)及24.0％ (6/25)的ALCL病例中存在3q26.1及3q26.31染色体区域的缺失.染色体区域2q21.3、6p22.1及3p25.1的获得在ALK阳性与ALK阴性ALCL病例中差异有统计学意义(P＜0.05).结论 ALCL存在着较为复杂的分子遗传学变化,即遗传学不平衡性.其中,染色体片段的扩增多于缺失.位于2q21.3、6p22.1及3p25.1的遗传学不平衡在ALK阳性和ALK阴性ALCL之间存在显著差异,表明ALK阳性和阴性ALCL所涉及的遗传学异常不同,可能涉及不同的信号转导通路.     

大细胞间变型T细胞淋巴瘤与EBV关系

目的：研究大细胞间变形Ｔ细胞淋巴瘤（ＡＬＣ－ＴＣＬ）与ＥＢＶ之间的关系，方法：应用免疫组织化学，聚合酶锭反应和ＲＮＡ原位杂交方法检测ＥＢＶ－ＤＮＡ的序列和ＥＢＶ编码ＲＮＡ。结果：检测的７例ＡＬＣ－ＴＣＬ，其中４例显示ＥＢＶ－ＤＮＡ和Ｅ－ＢＥＲ１／２阳性，两种检测方法的阳性率均为５７．１％（４／７），结论：ＡＬＣ－ＴＣＬ的发病与ＥＢＶ的感染的关系较密切。     

T细胞淋巴瘤中爱泼斯坦-巴尔病毒感染情况的研究

目的　通过检测不同类型T细胞淋巴瘤中爱泼斯坦 巴尔病毒 (EBV)基因编码产物EBERs的表达 ,探讨EBV与T细胞淋巴瘤的关系。方法　应用原位杂交的方法 ,对 6 0例经组织学和免疫组织化学确定的T细胞淋巴瘤中EBV编码的小RNAEBERs进行检测 ,并采用 1994年淋巴瘤REAL分类方案对 6 0例T细胞淋巴瘤进行分类 ,以进一步分析与EBV相关的T细胞淋巴瘤的临床病理特征。结果　发现 6 0例T细胞淋巴瘤中EBERs的检出率为 6 1.7% ,外周T细胞淋巴瘤的检出率为6 9 8%。结外淋巴瘤的检出率高于结内淋巴瘤 (P <0 .0 1)。EBERs在T细胞淋巴瘤中的血管中心性T细胞淋巴瘤、血管免疫母T细胞淋巴瘤、间变性大细胞淋巴瘤中的检出率分别为 17 18,2 2和 4 6 ,与外周T细胞淋巴瘤非特异型 (5 1.9% ,14 2 7)相比 ,差异有非常显著意义 (P <0 .0 1)。EBERs与T细胞淋巴瘤患者的性别、年龄和临床分期无关 (P <0 .0 5 )。结论　外周T细胞淋巴瘤与EBV感染有关 ,尤其是外周T细胞淋巴瘤中的血管中心性T细胞淋巴瘤、血管免疫母T细胞淋巴瘤和间变性大细胞淋巴瘤。     

皮肤原发性CD30阳性间变性大细胞淋巴瘤

目的 探讨皮肤原发性CD30阳性间变性大细胞淋巴瘤（ALCL）的临床及组织病理学特征,为病理诊断和鉴别诊断提供依据。方法 采用组织病理学及免疫组织化学SP法的白细胞共同抗原、CD20、CD30、CD45RO、CD68、上皮膜抗原、细胞角蛋白和HMB45染色对9例皮肤原发性CD30阳性ALCL进行观察。结果 患者年龄31-84岁（平均58.2岁）,男女之比2：1,均以皮肤丘疹或皮下包块就诊。组织形态;瘤细胞体积大,呈多形性、圆形或椭圆形,胞质丰富。核大,核仁明显,核分型象多,常见R-S样细胞和多核巨细胞,CD30阳性,其中6例同时表达CD45RO,非T非B型3例表达,随访：2例因肿瘤转移而死亡,2例肿瘤复发,5例无复发,健在。结论 皮肤原发性CD30阳性ALCL是具有独特形态特点及预后较好的肿瘤,根组织病理特征及CD30阳性,可与其他恶性肿瘤鉴别。     

原发性中枢神经系统淋巴瘤bcl-2蛋白和CD56的表达

目的：探讨原发性中枢神经系统淋巴瘤中bcl-2蛋白的表达情况及bcl-2蛋白阳性表达与CD56表达的相关性。方法：应用免疫组织化学S－P方法对21例原发性中枢神经系统淋巴瘤组织中bcl-2蛋白和CD56进行检测。结果：21例原发性中枢神经系统淋巴瘤中17例bcl-2蛋白表达阳性（81．0％）,阳性瘤细胞多呈弥漫分布,以中心细胞样细胞表达为主。21例原发性中枢神经系统淋巴瘤中bcl-2蛋白有较高的表达率,提示由bcl-2基因产物介导的细胞凋亡障碍与中枢神经系统淋巴瘤的发生有关;而原发性中枢神经系统淋巴瘤亦有CD56的表达,其可能与肿瘤侵袭性有关。     

皮肤原发性CD30阳性间变性大细胞淋巴瘤2例

例 1,患者男性 ,78岁。右下腹壁肿块 6个月 ,渐增大 ,近 1个月皮肤破溃不愈。体检 :右下腹壁 3ｃｍ× 2ｃｍ肿块 ,表面溃烂 ,周围皮肤红肿。全身浅表淋巴结未触及。行肿块局部切除。病理检查 :带皮肤肿块组织一块 ,4ｃｍ× 3ｃｍ× 2ｃｍ ,皮肤表面见 1ｃｍ× 0 8ｃｍ溃烂面 ,切面 2ｃｍ× 1 2ｃｍ ,灰红色 ,质嫩 ,呈“鱼肉样” ,与周围组织分界不清 ,紧贴表皮。镜下瘤细胞弥漫分布 ,间质少 ,浸润真皮层及皮下组织 ,部分区域表皮脚增生 ,未见瘤细胞侵犯表皮 ,无Ｐａｕｔｒｉｅｒ微脓肿。瘤细胞大 ,呈圆形、类圆形 ,胞质中等 ,淡伊红色 ,核…     

Expression of Epstein-Barr virus in Langerhans' cell histiocytosis

Langerhans' cell histiocytosis (LCH) is a proliferative histiocytic disorder of unknown etiology. We previously reported that Epstein-Barr virus (EBV) infects and proliferates in macrophages, and investigated the possibility that EBV exhibits etiologic effects in LCH. To detect EBV expression, paraffin sections from 17 LCH cases were examined by mRNA in situ hybridization for EBV BamHIW, Epstein-Barr virus nuclear antigen-2 (EBNA2), and Epstein-Barr virus-encoded small nonpolyadenylated RNA (EBER1) sequences, and by indirect immunofluorescence staining for EBNA2, latent membrane protein 1 (LMP1), and BamHIZ-coding leftward-reading frame 1 (BZLF1). To detect EBV DNA, polymerase chain reaction (PCR)-Southern blotting was used. All cases showed positive hybridization signals by BamHIW mRNA in situ hybridization. Also, 13 and 14 cases showed positive signals for EBNA2 and EBER1 RNA in situ hybridization, respectively. Furthermore, almost all cases exhibited fluorescence after immunofluorescence staining with monoclonal anti-EBNA2 and anti-BZLF1 antibodies, and 15 cases were positive after treatment with monoclonal anti-LMP1 antibody. PCR-Southern blotting detected an amplified EBER1 sequence in all 9 cases examined. EBV expression was confirmed in LCH using in situ hybridization and immunofluorescence. Furthermore, EBV DNA was also detected by PCR-Southern blotting. These positive results of BZLF1 suggest that EBV replicates in LCH tissues.     

Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature

Stacchini A, Barreca A, Demurtas A, Aliberti S, di Celle P F & Novero D
(2012) Histopathology  60, 452–459
Flow cytometric detection and quantification of CD56 (neural cell adhesion molecule, NCAM) expression in diffuse large B cell lymphomas and review of the literature Aim: To report unusual CD56 (neural cell adhesion molecule, NCAM) expression on diffuse large B cell lymphoma (DLBCL). Methods and results: CD56 expression was first detected and quantified on tissues obtained from five cases of DLBCL by flow cytometry (FC), then confirmed by immunohistochemistry. The CD56 expression pattern was heterogeneous among the cases [the molecular equivalent of soluble fluorochrome (MESF) level ranged from 2214 to 133 466]. All were CD10 and Bcl‐6 positive, suggesting their germinal centre origin; one was also CD5 positive. An extranodal presentation occurred in three of five cases. Conclusions: CD56 expression in B cell lymphoma is a rare occurrence. FC is able to identify aberrant immunophenotypes that can be useful in the identification and monitoring of B cell lymphoma subtypes. The presence of CD56 reported by the literature on certain DLBCL with extranodal presentation might be related to mechanisms involved in growth and expansion.     

CD56 positive diffuse large B-cell lymphoma: a case report and literature review

CD56 positive B-cell lymphoma is very rare. We experienced a case of CD56 positive diffuse large B-cell lymphoma, occurred in a young child. A 5-year-old girl complained with snoring and open mouth breathing. No any abnormality in laboratory or physical examination was present, except enlarged both tonsils. Bilateral tonsillectomy was performed. Cut sections of right tonsil showed a 2 cm size, solid mass. On microscopically, large monomorphic lymphoid cells were diffusely proliferated and showed positivity for CD20 and CD56 and negative for Epstein-Barr virus (EBV) polymerase chain reaction (PCR). Monoclonality was observed on immunoglobulin heavy chain gene rearrangement. This is a unique case with incidentally found and occurred in a young child.     

不同亚型T细胞淋巴瘤与EB病毒的关系

目的 :探讨不同组织学类型T细胞淋巴瘤 (TCL)与EBV感染的关系。方法 :对 83例 (6种类型 )TCL进行研究 ,包括低度恶性 30例 (其中小多形 2 1例、小淋巴细胞性 9例 ) ,高度恶性 5 3例 (其中大 /中多形 31例、淋巴母细胞性 9例、间变性大细胞性 7例、透明细胞性 6例 )。采用PCR检测EBV特征性的DNA序列 (EBV DNA)和ISH法检测EBV编码的RNA(EBER 1/2 )。结果 :每种类型TCL均有EBV的阳性表达 ,低度恶性组与高度恶性组之间EBER 1/ 2表达率差别有显著性 (P <0 0 5 )。结论 :各种类型TCL的发生发展均与EBV感染有关 ,但高度恶性组EBER 1/ 2的表达比低度恶性组更显著。     

Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan

CD56 is an important marker for prospecting clinicopathologic features of cytotoxic T-cell and natural killer (NK)/T-cell lymphomas. We examined 22 cases of subcutaneous panniculitis-like lymphoma and classified these into CD56-positive and CD56-negative groups. The 11 CD56-negative cases were mainly in the younger age group and had systemic subcutaneous nodules without ulceration. They exhibited subcutaneous invasion by medium-sized lymphoma cells, scattered erythrophagocytosis, patchy necrosis, and little tumor invasion in the superficial dermis. Their lymphoma cells had characteristics of CD3 epsilon-, CD8-, TcR beta F1-, T-cell intracellular antigen (TIA)1-, and granenzyme B-positive cytotoxic T cells and were negative for apoptosis-promoting proteins CD95 (Fas), Bax, CPP32 (caspase 3), and p53 (DO7). Ten patients were alive despite clinical signs of hemophagocytic syndrome and relapses in 7 cases. The 11 CD56-positive cases had systemic ulcerative skin tumors composed of pleomorphic lymphoma cells with massive necrosis and little erythrophagocytosis involving the subcutis and also often the whole dermis. Their tumor cells were positive for CD3 epsilon, TIA1, granenzyme B, CD95, CD95L (Fas ligand), Bax, and CPP32. Three cases were of the TcR beta F1-positive phenotype, 1 was of the TcR gamma/delta-positive T-cell phenotype, and 6 were of the TcR beta F1- and TcR gamma/delta-negative NK/T-cell phenotype. Six cases were p53 (DO7) positive. Seven cases had complications of liver dysfunction and cytopenia, and 8 died of disease. One CD56-negative case and 3 CD56-positive cases had nuclear signals of Epstein-Barr virus-encoded RNA in their lymphoma cells. The 2 groups had significantly (P <0.01) different prognoses by Kaplan-Meier and log-rank methods. Patients with CD56-negative and CD56-positive groups had statistically different clinicopathologic, immunohistologic, and functional findings and prognoses.